
What We're Reading: Cheaper Hepatitis C Drugs; Pharma Discount Rollback; HHS Pulls Fetal Tissue Research
Gilead Sciences will sell authorized generics of its blockbuster hepatitis C drugs Epclusa and Harvoni; the pharmaceutical industry inserted a measure into an opioid bill to reverse discounts they would be required to give next year to seniors enrolled in Medicare Part D plans; the Trump administration has terminated a contract with a fetal tissue firm after being criticized by antiabortion groups and Republican lawmakers.
Gilead Sciences to Sell Authorized Generics of Hepatitis C Drugs
Gilead Sciences will sell authorized generics of its blockbuster hepatitis C drugs Epclusa and Harvoni,
Pharma Industry Seeks to Reverse Planned Increase in Medicare Drug Discounts
The pharmaceutical industry inserted a measure into an opioid bill to reverse discounts they would be required to give next year to seniors enrolled in Medicare Part D plans,
HHS Cancels Fetal Tissue Research Contract
The Trump administration has terminated a contract with a fetal tissue firm after being criticized by antiabortion groups and Republican lawmakers,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.